{"id":20123,"date":"2024-12-03T22:39:36","date_gmt":"2024-12-03T14:39:36","guid":{"rendered":"https:\/\/flcube.com\/?p=20123"},"modified":"2024-12-28T22:47:12","modified_gmt":"2024-12-28T14:47:12","slug":"regimmune-and-san-fu-biotech-ink-deal-for-rgi-2001-development-in-asia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20123","title":{"rendered":"REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia"},"content":{"rendered":"\n<p>Taiwan-based biotechnology company REGiMMUNE Ltd has announced the signing of an out-license agreement with San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/4755:TPE\">TPE: 4755<\/a>). Under the terms of the deal, REGiMMUNE will transfer the development and commercial rights of its pipeline candidate, RGI-2001, to SFB for major markets in Asia. RGI-2001 is being developed as a prophylaxis for acute graft-versus-host disease (aGvHD).<\/p>\n\n\n\n<p><strong>RGI-2001: A Potential First-in-Class Treatment for aGvHD<\/strong><br>RGI-2001 is a small-molecule drug with a novel mechanism of action, which positions it as a potentially first-in-class therapy for the prevention of aGvHD. This condition is associated with allogeneic hematopoietic stem cell transplantation (HSCT) and RGI-2001 is expected to offer improvements over current prevention therapies. The drug has already received orphan drug designation from the US FDA in 2012 and has successfully completed Phase II trials in the United States, showing positive results.<\/p>\n\n\n\n<p><strong>Collaboration and Development Plans<\/strong><br>REGiMMUNE and SFB will collaborate on the further development of RGI-2001, with plans to file an Investigational New Drug (IND) application with Taiwan\u2019s Food and Drug Administration before the end of 2023. Financial terms of the agreement include development milestones and royalties on future net sales, the specifics of which have not been disclosed.<\/p>\n\n\n\n<p><strong>Significance of aGvHD and Unmet Needs<\/strong><br>GvHD occurs when the immune cells from the graft recognize the host&#8217;s body as foreign and initiate an attack on the recipient&#8217;s cells or organs. Patients who develop aGvHD following allogeneic HSCT face a significantly increased risk of mortality. Clinically, aGvHD develops in 20-40% of HLA-matched related and unrelated allogeneic HSCT cases, highlighting a significant unmet need in the market for more effective prophylactic treatments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Taiwan-based biotechnology company REGiMMUNE Ltd has announced the signing of an out-license agreement with San&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2987,2988],"class_list":["post-20123","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-regimmune","tag-san-fu-chemical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Taiwan-based biotechnology company REGiMMUNE Ltd has announced the signing of an out-license agreement with San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd (TPE: 4755). Under the terms of the deal, REGiMMUNE will transfer the development and commercial rights of its pipeline candidate, RGI-2001, to SFB for major markets in Asia. RGI-2001 is being developed as a prophylaxis for acute graft-versus-host disease (aGvHD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20123\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20123\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-03T14:39:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-28T14:47:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20123#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20123\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia\",\"datePublished\":\"2024-12-03T14:39:36+00:00\",\"dateModified\":\"2024-12-28T14:47:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20123\"},\"wordCount\":292,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"REGiMMUNE\",\"San Fu Chemical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20123#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20123\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20123\",\"name\":\"REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-12-03T14:39:36+00:00\",\"dateModified\":\"2024-12-28T14:47:12+00:00\",\"description\":\"Taiwan-based biotechnology company REGiMMUNE Ltd has announced the signing of an out-license agreement with San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd (TPE: 4755). Under the terms of the deal, REGiMMUNE will transfer the development and commercial rights of its pipeline candidate, RGI-2001, to SFB for major markets in Asia. RGI-2001 is being developed as a prophylaxis for acute graft-versus-host disease (aGvHD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20123#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20123\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20123#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia - Insight, China&#039;s Pharmaceutical Industry","description":"Taiwan-based biotechnology company REGiMMUNE Ltd has announced the signing of an out-license agreement with San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd (TPE: 4755). Under the terms of the deal, REGiMMUNE will transfer the development and commercial rights of its pipeline candidate, RGI-2001, to SFB for major markets in Asia. RGI-2001 is being developed as a prophylaxis for acute graft-versus-host disease (aGvHD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20123","og_locale":"en_US","og_type":"article","og_title":"REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=20123","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-03T14:39:36+00:00","article_modified_time":"2024-12-28T14:47:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20123#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20123"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia","datePublished":"2024-12-03T14:39:36+00:00","dateModified":"2024-12-28T14:47:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20123"},"wordCount":292,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["REGiMMUNE","San Fu Chemical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20123#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20123","url":"https:\/\/flcube.com\/?p=20123","name":"REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-12-03T14:39:36+00:00","dateModified":"2024-12-28T14:47:12+00:00","description":"Taiwan-based biotechnology company REGiMMUNE Ltd has announced the signing of an out-license agreement with San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd (TPE: 4755). Under the terms of the deal, REGiMMUNE will transfer the development and commercial rights of its pipeline candidate, RGI-2001, to SFB for major markets in Asia. RGI-2001 is being developed as a prophylaxis for acute graft-versus-host disease (aGvHD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20123#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20123"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20123#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"REGiMMUNE and San Fu Biotech Ink Deal for RGI-2001 Development in Asia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20123"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20123\/revisions"}],"predecessor-version":[{"id":20125,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20123\/revisions\/20125"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}